Orenitram (treprostinil; United Therapeutics) Drug Profile 2016-2025 - ResearchAndMarkets.com
The "Orenitram" report has been added to ResearchAndMarkets.com's offering.
Orenitram (treprostinil; United Therapeutics) is a novel formulation of the prostacyclin analog treprostinil, formulated using Supernus Pharmaceuticals' drug delivery technology, allowing for twice-daily oral dosing. Orenitram represents the continuation of United Therapeutics' PH portfolio, led by intravenous Remodulin.
Analyst Outlook
Although Orenitram (treprostinil; United Therapeutics) was approved as the first oral prostacyclin analog in the US, addressing an important unmet need of the time, its clinical data are weak and consequently the drug has only made a minor impact on the pulmonary hypertension (PH) market.
Moreover, newer brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) poses tough competition in the oral prostacyclin class. To better position its brand, United Therapeutics is investigating Orenitram's potential in PH associated with left heart disease (PH-LHD) and aiming to use morbidity evidence from the FREEDOM-EV study that could support EU approval.
While United Therapeutics is investing in further developing Orenitram, the author ultimately does not foresee Orenitram outcompeting Uptravi as the former's clinical profile is unconvincing. Nevertheless, Orenitram is still expected to indirectly benefit from the TRITON trial investigating the value of triple combination therapy with an oral prostacyclin
Key Topics Covered:
OVERVIEW
Drug Overview
Product Profiles
Orenitram : Pulmonary hypertension
LIST OF FIGURES
Orenitram for pulmonary hypertension - SWOT analysis
The authors drug assessment summary of Orenitram for pulmonary hypertension
Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country, 2016-25
LIST OF TABLES
Orenitram drug profile
Orenitram pivotal trial data in pulmonary hypertension
Orenitram late-phase data in pulmonary hypertension
Orenitram ongoing late-phase trials in pulmonary hypertension
Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016-25
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland.
The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance --
2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which...
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...